Guerbet SA (EPA:GBT)

Market Cap	116.44M -57.9%
Revenue (ttm)	798.67M -6.2%
Net Income	-108.33M
EPS	-8.59
Shares Out	12.62M
PE Ratio	n/a
Forward PE	5.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,225
Open	9.10
Previous Close	9.10
Day's Range	9.10 - 9.28
52-Week Range	8.01 - 23.70
Beta	0.99
Analysts	Sell
Price Target	11.60 (+25.68%)
Earnings Date	Sep 15, 2026

About Guerbet

Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconnected solution; and Artirem, a gadoteric acid. The company also provides OptiStar Elite, a dual head contrast delivery system with an ultrasonic motor; ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1901
• Employees: 2,746
• Stock Exchange: Euronext Paris
• Ticker Symbol: GBT

Analyst Summary

According to 3 analysts, the average rating for GBT stock is "Sell." The 12-month stock price target is €11.60, which is an increase of 25.68% from the latest price.

Price Target

€11.60

(25.68% upside)

Analyst Consensus: Sell

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 23, 2026

Data Sources Report a data error